article thumbnail

ADCs Pipeline Update: Avacta Partners with ADC Therapeutics

Roots Analysis

Currently, product licensing agreements, technology licensing agreements, research and development agreements and clinical trial agreements are the common types of partnerships inked by developers that are currently focused on the development of ADCs pipeline. In nature, they are made by a group of bacteria known as actinomycetes.

article thumbnail

Pfizer’s pill cuts COVID deaths and hospitalisations by 90%

pharmaphorum

There have also been come concerns about the risk of birth defects with molnupiravir due to its mechanism of action that can lead to DNA changes, and Pfizer has been quick to point out that it has found no evidence of “mutagenic DNA interactions” with its protease inhibitor.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

The Pharma Data

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” About INOVIO’s DNA Medicines Platform. mg and 2.0

DNA 40
article thumbnail

PFIZER SEEKS EMERGENCY USE AUTHORIZATION FOR NOVEL COVID-19 ORAL ANTIVIRAL CANDIDATE

The Pharma Data

Pfizer has begun and will continue to invest up to roughly$ 1 billion of its own finances to support the manufacturing and distribution of this investigational treatment seeker. In preclinical studies, PF-07321332 didn’t demonstrate substantiation of mutagenic DNA relations.

HR 52
article thumbnail

Pfizer to supply UNICEF up to 4 million treatment courses of novel COVID-19 oral treatment for low- and middle-income countries

The Pharma Data

Pfizer continues to invest to support the manufacturing and distribution of PAXLOVID, including exploring potential contract manufacturing options. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.

article thumbnail

ADC Cytotoxic Payloads / Warheads and Rise in its Demand

Roots Analysis

However, several ADC developers do not have the in-house capabilities to manufacture cytotoxic payload on a commercial scale and tend to rely on contract manufacturers. As per the estimates, 70-80% of ADC manufacturing operations are outsourced. Want additional details on the ADC Payloads / Warheads Developers?

article thumbnail

The challenges and trends of cell & gene therapies 

Drug Discovery World

Indeed, the growth of the cell and gene therapy market, coupled with the demand that the pandemic placed on manufacturing capacity, means the industry faces shortages of these crucial materials. Another area that can be tough to manoeuvre is IP, as we saw recently over the disputes surrounding CRISPR. Workforce .